Literature DB >> 20829807

Avastin's commercial march suffers setback.

Malorye Allison.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20829807     DOI： 10.1038/nbt0910-879

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Authors:  Valentina Guarneri; David Miles; Nicholas Robert; Véronique Diéras; John Glaspy; Ian Smith; Christoph Thomssen; Laura Biganzoli; Tanya Taran; PierFranco Conte
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

2.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

3.  Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.

Authors:  Gottfried E Konecny; Y Gloria Meng; Michael Untch; He-Jing Wang; Ingo Bauerfeind; Melinda Epstein; Petra Stieber; Jean-Michel Vernes; Johnny Gutierrez; Kyu Hong; Malgorzata Beryt; Hermann Hepp; Dennis J Slamon; Mark D Pegram
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531
  3 in total
  4 in total

Review 1.  Benefit-risk assessment of bevacizumab in the treatment of breast cancer.

Authors:  Rodrigo Dienstmann; Felipe Ades; Kamal S Saini; Otto Metzger-Filho
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  Can cancer clinical trials be fixed?

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2011-01       Impact factor: 54.908

Review 3.  Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer.

Authors:  Jordan A Harry; Mark L Ormiston
Journal:  Front Oncol       Date:  2021-12-03       Impact factor: 6.244

4.  Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.

Authors:  José R Rossari; Otto Metzger-Filho; Marianne Paesmans; Kamal S Saini; Alessandra Gennari; Evandro de Azambuja; Martine Piccart-Gebhart
Journal:  J Oncol       Date:  2012-09-12       Impact factor: 4.375
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.